DiaMedica Therapeutics (DMAC)
(Delayed Data from NSDQ)
$4.14 USD
+0.11 (2.73%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $4.16 +0.02 (0.48%) 6:02 PM ET
2-Buy of 5 2
D Value F Growth A Momentum D VGM
Income Statements
Fiscal Year end for DiaMedica Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 21 | 14 | 14 | 13 | 12 |
Income After Depreciation & Amortization | -21 | -14 | -14 | -13 | -12 |
Non-Operating Income | 2 | 0 | 0 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -19 | -14 | -14 | -12 | -11 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -19 | -14 | -14 | -12 | -11 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -19 | -14 | -14 | -12 | -11 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -22 | -14 | -13 | -13 | -12 |
Depreciation & Amortization (Cash Flow) | -1 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -21 | -14 | -14 | -13 | -12 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 32.57 | 26.44 | 20.77 | 15.68 | 11.99 |
Diluted EPS Before Non-Recurring Items | -0.60 | -0.52 | -0.65 | -0.78 | -0.89 |
Diluted Net EPS (GAAP) | -0.60 | -0.52 | -0.65 | -0.78 | -0.89 |
Fiscal Year end for DiaMedica Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 5.64 | 5.75 | 5.85 | 5.16 | 4.74 |
Income After SG&A, R&D, and Dept/Amort Expenses | -5.64 | -5.75 | -5.85 | -5.16 | -4.74 |
Non-Operating Income | 0.53 | 0.60 | 0.71 | 0.69 | 0.27 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -5.11 | -5.14 | -5.14 | -4.46 | -4.47 |
Income Taxes | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -5.12 | -5.15 | -5.16 | -4.47 | -4.48 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -5.12 | -5.15 | -5.16 | -4.47 | -4.48 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 38.07 | 37.96 | 36.86 | 37.95 | 27.31 |
Diluted EPS Before Non-Recurring Items | -0.13 | -0.14 | -0.14 | -0.12 | -0.16 |
Diluted Net EPS (GAAP) | -0.13 | -0.14 | -0.12 | -0.12 | -0.16 |